{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:22:14Z","timestamp":1787394134549,"version":"build-2736575974"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>With the prevalence of non-alcoholic fatty liver disease (NAFLD) increasing worldwide, many noninvasive techniques have been used to improve its diagnosis. Recently, the serum uric acid\/creatinine (sUA\/sCr) ratio was identified as an indicator of fatty liver disease. Therefore, we examined the relationship between sUA\/sCr levels and ultrasound-diagnosed NAFLD in Korean adults.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study included 16,666 20-year-olds or older who received health checkups at a university hospital\u2019s health promotion center from January to December 2021. Among them, 11,791 non-patients with and without NAFLD were analyzed, excluding those without abdominal ultrasound, those without data on fatty liver, cancer, or chronic kidney disease severity, those with a history of alcohol abuse, and those with serum hs-CRP &lt;5 mg\/L. The odds ratio (OR) and 95% confidence interval (CI) of the sUA\/sCr ratio according to the presence or absence of fatty liver disease and severity were calculated after correcting for confounding variables using logistic regression analysis. The receiver operating characteristic (ROC) curve and area under the curve (AUC) of the sUA\/sCr ratio confirmed and compared the sensitivity and specificity of NAFLD and serum uric acid.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>sUA\/sCr increased with fatty liver severity, and the post-correction OR in the NAFLD group was 1.183 (95% CI: 1.137\u20131.231) compared to the group without NAFLD. Concerning the fatty liver severity, the post-correction OR in the mild NAFLD group increased to 1.147 (95% CI: 1.099\u20131.196), and that in the moderate-to-severe NAFLD group increased to 1.275 (95% CI: 1.212\u20131.341) compared to the group without NAFLD. The sensitivity of sUA\/sCr to fatty liver severity was 57.9% for the non-NAFLD group, 56.7% for the mild NAFLD group, and 59.0% for the moderate-to-severe NAFLD group; the specificity of sUA\/sCr to fatty liver severity 61.4% for the non-NAFLD group, 57.3% for the mild NAFLD group, and 65.2% for the moderate-to-severe NAFLD group.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>NAFLD severity is associated with sUA\/sCR.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0288666","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T17:28:54Z","timestamp":1689701334000},"page":"e0288666","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["The correlation between NAFLD and serum uric acid to serum creatinine ratio"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9645-4106","authenticated-orcid":true,"given":"Jangwon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-2866","authenticated-orcid":true,"given":"Hyun","family":"Joe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwang-Sik","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Hun","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"pone.0288666.ref001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"P. Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"pone.0288666.ref002","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fay liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"G Marchesini","year":"2003","journal-title":"Hepatology"},{"issue":"9468","key":"pone.0288666.ref003","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"R. H. Eckel","year":"2005","journal-title":"The Lancet"},{"key":"pone.0288666.ref004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"pone.0288666.ref005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/met.2008.0070","article-title":"Health Care Utilization and costs by metabolic syndrome risk factors.","volume":"7","author":"DM Boudreau","year":"2009","journal-title":"Metabolic Syndrome and Related Disorders"},{"issue":"1","key":"pone.0288666.ref006","first-page":"47","article-title":"The Effects of the Metabolic Syndrome on the Total Medical Charge.","volume":"27","author":"KY Kim","year":"2017","journal-title":"Health Policy and Management"},{"issue":"3","key":"pone.0288666.ref007","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3350\/cmh.2021.0178","article-title":"KASL Clinical Practice Guidelines: Management of nonalcoholic fatty liver disease","volume":"27","author":"SH Kang","year":"2021","journal-title":"Clinical and Molecular Hepatology"},{"key":"pone.0288666.ref008","first-page":"14","article-title":"Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy","author":"T Sudjaritruk","year":"2019","journal-title":"PLOS ONE"},{"key":"pone.0288666.ref009","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: Prevalence, incidence and risk factors.","volume":"11","author":"CF Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"pone.0288666.ref010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.","volume":"15","author":"T Bardin","year":"2017","journal-title":"BMC Med."},{"issue":"48","key":"pone.0288666.ref011","doi-asserted-by":"crossref","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"MA Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"issue":"10","key":"pone.0288666.ref012","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/labinvest.2014.98","article-title":"Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes","volume":"94","author":"YJ Choi","year":"2014","journal-title":"Lab Invest"},{"key":"pone.0288666.ref013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1570161115666170621082237","article-title":"Can serum uric acid lowering therapy contribute to the prevention or treatment of nonalcoholic fatty liver disease?","volume":"16","author":"P Paschos","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"pone.0288666.ref014","doi-asserted-by":"crossref","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","article-title":"A causal role for uric acid in fructose-induced metabolic syndrome","volume":"290","author":"T Nakagawa","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"pone.0288666.ref015","doi-asserted-by":"crossref","first-page":"e11578","DOI":"10.1371\/journal.pone.0011578","article-title":"High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study","volume":"5","author":"C Xu","year":"2010","journal-title":"PloS One"},{"issue":"5","key":"pone.0288666.ref016","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2008.11.021","article-title":"Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study","volume":"50","author":"Y Li","year":"2009","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0288666.ref017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.5009\/gnl.2010.4.3.378","article-title":"Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study.","volume":"4","author":"JW Lee","year":"2010","journal-title":"Gut Liver"},{"issue":"8","key":"pone.0288666.ref018","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24590","article-title":"Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States","volume":"36","author":"R Wang","year":"2022","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"pone.0288666.ref019","article-title":"The serum uric acid\/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population","author":"S Sookoian","year":"2022","journal-title":"J Physiol Biochem"},{"issue":"2","key":"pone.0288666.ref020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/met.2020.0086","article-title":"Association of the serum uric acid-to-creatinine ratio with nonalcoholic fatty liver disease diagnosed by computed tomography","volume":"19","author":"YB Seo","year":"2021","journal-title":"Metabolic Syndrome and Related Disorders"},{"key":"pone.0288666.ref021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12876-022-02500-w","article-title":"Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol","volume":"22","author":"X Wang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"pone.0288666.ref022","first-page":"11","article-title":"C-peptide: A mediator of the association between serum uric acid to creatinine ratio and non-alcoholic fatty liver disease in a Chinese population with normal serum uric acid levels","author":"C Ma","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"2","key":"pone.0288666.ref023","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4093\/jkd.2017.18.2.102","article-title":"Diagnosis of non-alcoholic fatty liver disease based on clinical and laboratory data","volume":"18","author":"Y. Lee","year":"2017","journal-title":"The Journal of Korean Diabetes"},{"issue":"6","key":"pone.0288666.ref024","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"N Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"pone.0288666.ref025","volume-title":"AUDIT the alcohol use disorders identification test: guidelines for use in primary care","author":"TF Babor","year":"2001","edition":"2"},{"issue":"3","key":"pone.0288666.ref026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1757975919854301","article-title":"Development of the korean global physical activity questionnaire: Reliability and validity study","volume":"27","author":"J Lee","year":"2019","journal-title":"Global Health Promotion"},{"key":"pone.0288666.ref027","first-page":"2023","volume":"3","journal-title":"GPAQ Analysis Guide\u2014World Health Organization"},{"issue":"2","key":"pone.0288666.ref028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7570\/jomes21022","article-title":"2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea","volume":"30","author":"BY Kim","year":"2021","journal-title":"J Obes Metab Syndr"},{"issue":"7","key":"pone.0288666.ref029","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5124\/jkma.2022.65.7.388","article-title":"Current status of obesity treatment in Korea: Based on the 2020 korean society for the study of obesity guidelines for obesity management","volume":"65","author":"EJ Rhee","year":"2022","journal-title":"Journal of the Korean Medical Association"},{"key":"pone.0288666.ref030","first-page":"10","author":"World Health Organization","year":"2000","journal-title":"Obesity: Preventing and managing the global epidemic"},{"issue":"12","key":"pone.0288666.ref031","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.5124\/jkma.2005.48.12.1165","article-title":"Cut-off values of waist circumference for abdominal obesity among Koreans","volume":"48","author":"H. Park","year":"2005","journal-title":"Journal of the Korean Medical Association"},{"issue":"1","key":"pone.0288666.ref032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/(SICI)1097-0096(199601)24:1<25::AID-JCU4>3.0.CO;2-N","article-title":"Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes","volume":"24","author":"H Osawa","year":"1996","journal-title":"J Clin Ultrasound"},{"issue":"2","key":"pone.0288666.ref033","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15616\/BSL.2017.23.2.118","article-title":"Clinical usefulness of serum uric acid and resting heart rate in the diagnosis of metabolic syndrome in Korean adults","volume":"23","author":"KA Shin","year":"2017","journal-title":"Biomedical Science Letters"},{"issue":"2","key":"pone.0288666.ref034","first-page":"218","article-title":"The Association between Serum Uric Acid Levels and Insulin Resistance and Secretion in Prediabetes Mellitus: A Cross-Sectional Study","volume":"49","author":"Y Wu","year":"2019","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"pone.0288666.ref035","first-page":"362","article-title":"Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease","volume":"7","author":"DH Akhtar","year":"2019","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"pone.0288666.ref036","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1590\/1806-9282.20201005","article-title":"The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: The ABUND study","volume":"67","author":"MA Kosekli","year":"2021","journal-title":"Revista Da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"issue":"6","key":"pone.0288666.ref037","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease","volume":"41","author":"RJ Johnson","year":"2003","journal-title":"Hypertension"},{"issue":"26","key":"pone.0288666.ref038","doi-asserted-by":"crossref","first-page":"8377","DOI":"10.3748\/wjg.v20.i26.8377","article-title":"Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment","volume":"20","author":"NC Leite","year":"2014","journal-title":"World J Gastroenterol"},{"key":"pone.0288666.ref039","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0294801","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T17:29:18Z","timestamp":1689701358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288666"}},"subtitle":[],"editor":[{"given":"Gulali","family":"Aktas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0288666","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0294801","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}